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1. Abstract
Colorectal Carcinoma (CRC) is one of the deadliest cancers in the world, with 150,000 new cases
annually in the United States. Traditional treatments include chemotherapy and invasive surgery;
however, research has shown that only 25% of patients that undergo traditional treatment have a
positive result. Immunotherapy is an emerging form of cancer treatment that utilizes the patients’
immune system to fight cancer cells by targeting inflammation, which plays a large role in the
proliferation and metastasis of cancer cells.
Tumor-associated macrophages (TAMs) are immune cells that affect the inflammatory
microenvironment of tumors. TAMs are M1 in the early stages of tumors, and are phagocytic and
cytotoxic. However, these macrophages shift towards M2 as the tumors grow, which promote
tumorigenesis, angiogenesis, and immunosuppression in CRC. M2 macrophage density may
indicate the pro-tumor effects of TAMs, and it is expected that fewer M2 macrophages is correlated
with a higher survival rate of patients with cancer.
The central hypothesis in this study is that blockade of TAM recruitment via immunotherapy
would decrease M2 macrophages in the tumor microenvironment, resulting in a more treatable
tumor. Monocyte chemoattractant protein-1 (CCL-2) is a cytokine secreted by tumors known to
recruit monocytes that differentiate into TAMs. In our study, we examined the effects of CCL-2
blockade in a murine allograft model of CRC.
Thirty 10-week old Balb/c mice were injected subcutaneously with 1x105 CT26 murine colon
carcinoma cells. Fifteen mice received anti-CCL-2 immunotherapy, and 15 control mice received
saline. Tumor allografts grew until they reached 75 mm3. Tumor sections were stained for M2
macrophages and total cells, and then imaged to determine the M2 macrophage density. On Day
+
10, the tumors were 13.02 +
−3.04 and 11.03 −3.99 times their original sizes, and M2 macrophage
+
+
densities were 593.3 −9.0 and 559.2−7.0 M2 macrophages/mm2 for the control and treated mice
respectively.
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2. Summary
The biomedical engineering department was started at the University of Arkansas in 2012,
and I have been fortunate enough to do undergraduate research for the past 4 years under the
supervision of one of the founding members of the department, Dr. Muldoon. During my freshman
year, I took an undergraduate research class in which another student and I worked in Dr.
Muldoon’s biomedical engineering lab. We used a multi-photon microscope and computer
programs for cell image analysis and presented at The Freshman Engineering Program’s Honors
Research Symposium. I remained in the lab and spent the next two years being an assistant to a
graduate student and becoming familiar with the equipment. I assisted with the use of the multiphoton microscope to image live tissue for fluorescence, and collected preliminary data to begin a
project on multispectral unmixing of images of live tissue. I also designed and constructed a
blackout box to enclose the multiphoton microscope to block excess light in order to enhance the
integrity and quality of acquired images.
In the Spring of 2017, I was awarded a State Undergraduate Research Fellowship to fund
an original research project. I have been working with Dr. Muldoon and a graduate student to
develop a protocol for observing immune cells on cancerous tumors in mice and using
spectroscopy methods to correlate the findings with immune response. The specific cells I am
focusing on are tumor-associated macrophages and their correlation to tumor progression and
inhibition. I presented the preliminary findings at the Gulf Coast Undergraduate Research
Symposium at Rice University in Fall 2017.
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3. Introduction
3.1 Background
Colorectal cancer (CRC) is the 3rd deadliest cancer worldwide, and there are 150,000 new
cases annually in the US. [1] Cancer progression is designated in stages. Progression through each
stage involves the altering of
genes that allow tumor cells to
bypass growth control and
signals for cell apoptosis. [2]
Figure
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Figure 1. Representative diagram of a normal colon vs. one that
contains cancer cells in the form of tumors. [18]

locally advanced (stage II and III) CRC consists of chemotherapy followed by surgery. 5fluorouracil (5-FU) is a pyrimidine that is among the most commonly used chemotherapy agents
to treat CRC in both early and late stages. [2] However, only about 25% of patients achieve positive
results from treatment with 5-FU alone. [3] Part of the low success rate can be attributed to patientspecific reaction to the chemotherapy.
A promising field called immunotherapy has emerged which involves optimizing the
patients’ specific immune system to combat cancer cells. Combination therapy including both
conventional 5-FU and immunotherapy may improve overall clinical outcomes in patients with
locally advanced disease. [4] Common targets of immunotherapy are the biochemical pathways
involved in inflammation, which provides conditions that allow tumor cells to proliferate and
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metastasize.

[4]

Therefore,

immunotherapy which targets
inflammation may have a
beneficial role in treating CRC.
Figure 2 provides a visual aid
to compare traditional cancer
therapies with immunotherapy
treatments. As can be seen in
the
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like

traditional
drugs

Figure 2. A diagram comparing traditional cancer therapies
and immunotherapy. [19]

and

radiation kill both cancer cells and healthy cells, whereas immunotherapy treatment uses a
patients’ immune system to only kill cancer cells.
Inflammation is a complex cascade, but studies suggest that it is a contributing factor to
tumor growth because it provides conditions that allow tumor cells to grow, survive, and become
metastatic. [5] Inflammation can be initiated or encouraged by tumor cells, or by cells recruited to
the tumor microenvironment which are required for the progression of tumors. [5] It is becoming
more prevalently accepted that there is an immunosuppressive micro-environment within tumors,
due to both cancer and immune cells, that limits the effectiveness of immunotherapy. [4] For
successful treatments, it is common to involve a second agent to alter the tumor, such as combining
other drugs with a chemotherapy agent to enhance its effect, or to combine chemotherapy with
radiation. [4] Scientists are taking this knowledge and are considering alternative agents to find
the most effective enhancers to allow the chemotherapy to have maximum effect. One method that
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is being explored, and is the focus of the second phase of this experiment, is the effect of
immunotherapy in addition to chemotherapy on M2 macrophage density in cancerous tumors.
Tumor-associated macrophages (TAMs) are primary immune cells that affect the microenvironment of tumors. TAMs in the early stages of tumors are known as M1 or “classically
activated” type, and are phagocytic, cytotoxic, and present antigens well. [6] As the tumor
continues to grow, however,
macrophages change to a M2
or

“alternatively activated”

type. M1 and M2 TAMs differ
based on receptor expression,
antigen-presenting
function,

and

ability,
cytokine

Figure 3. A diagram of the transition from M1 to M2
phenotypes as cancer progresses. [6]

production. [7] M2 TAMs have properties that promote tumors, and are angiogenic and
immunoinhibitory. [8] Similar to a wound healing response, macrophages enter the
microenvironment and signal for other molecules to be recruited to increase the formation of new
blood vessels. This, in turn, increases oxygenation and tumor size. [6] By determining the TAM
phenotype, one could determine the density of M2 macrophages in a tumor, which could be used
as a vital indicator of the effectiveness of immunotherapy treatment. Considering the differing
functions of the macrophages, it is expected that a larger density of M2 macrophages would be
correlated with a higher survival rate of patients with cancer. [9]
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3.2 Rationale
The central hypothesis in this study is that blockade of TAM recruitment via
immunotherapy techniques would decrease the number of M2-polarized macrophages in the tumor
microenvironment, potentially resulting in a more treatable tumor. A hypoxic microenvironment
is common to malignant tumors. [10] As a result of the lack of oxygen, the cancer cells will activate
the transcription of downstream target genes. [11] TAM recruitment into tumors is modulated via
a complex series of cytokines and other signaling molecules. Pyruvate kinase M2 (PKM2) is an
enzyme that catalyzes the last step of glycolysis, and is highly expressed in CRC. [11] In CRC
cells, PKM2 aids macrophage recruitment via nuclear factor-𝜅𝛽 (NF-𝜅𝛽) signaling pathwaymediated chemoattractant protein-1 (CCL-2) expression. [11] CCL-2 is a cytokine that is normally
secreted by cancerous tumors and is known to recruit monocytes in peripheral blood via
chemotaxis, which subsequently differentiate into TAMs. [13] The polarization of TAMs into M1
or M2 is dependent on transcriptional regulators. [12] Hypoxia-inducible factor-1 (HIF-1) is a
transcription factor that promotes a change in energy metabolism from oxidative phosphorylation
to glycolysis and increases oxygenation. [14] HIF-1 acts as a regulator and is linked to the
proliferation, migration, and metastasis of tumor cells. [15] M2 macrophages aid in tumor growth
via inflammation, angiogenesis, extracellular matrix formation, and immunosuppression by
contact with other cells or by producing growth factors, chemokines, and angiogenic substances
such as inteleukin (IL)-10, IL-8, IL-6, IL-1ß, and tumor necrosis factor-𝛼 (TNF- 𝛼), and tumor
growth factor-ß (TGF- ß). [16] In our study, we examined the effects of using anti-CCL-2 to block
monocyte infiltration in the tumor microenvironment of a murine allograft model of CRC. An
allograft model consists of mouse cells in a mouse tumor. The cancer cells are of the mouse species
to have the mice remain immunologically intact for the introduction and development of the CRC.
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3.3 Significance of Work
This project is important because there are some aspects of TAMs that are unknown, such
as how M2 macrophage density affects prognostic outcomes and how the relative number and
types of TAMs in a tumor affect response to immunotherapy. The results of this experiment will
be used to guide immunotherapy in CRC by quantifying the effects that blocking TAM recruitment
via CCL-2 blockade has on the M2 macrophage density. Future work will investigate the effects
of combining immunotherapy with traditional 5-FU chemotherapy.

4. Materials and Methods
4.1 Murine Models
Thirty nine-week-old female Balb/c mice (strain: 000651, The Jackson Laboratory, ME,
USA) were purchased by a graduate student for this study. This study was approved by the
University of Arkansas Institutional Animal Care and Use Committee (IACUC #18060). The mice
were housed in groups of three in five cages at 23°C ± 1°C and 40-60% humidity on a 12:12 hour
light-dark cycle. Food (8640, Teklad) and water was provided ad libitum. All thirty mice were
allowed to acclimate for seven days after arrival prior to the start of the study. After one week of
acclimation, the left flanks of the now 10-week old Balb/c mice were shaved and Nair was applied
for one minute to locally remove hair.

4.2 Tumor Model and Therapy
The 30 Balb/c mice underwent tumor allotransplantation by a graduate student. A colon
carcinoma cell line derived from the Balb/c mouse strain, CT26 (ATCC®, CRL-2638TM), was kept
in Roswell Park Memorial Institute (RPMI)-1640 medium (ATCC®, 30-2001TM) in addition to
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10% fetal bovine serum (ATCC®, 30-2020), 1% antibiotic antimyocotic solution (Sigma-Aldrich,
A5955-100ML), and 0.2% amphotericin B/gentamicin (Thermo Fisher Scientific, R015010) at
37°C and 5% CO2. CT26 cells were brought to the third passage (P3), and 1x105 CT26 cells in
sterile saline were injected subcutaneously into the left flank by the graduate student. It took an
3
average of 12.9 +
− 1.9 days to reach 75mm , which was designated as Day 0.

Fifteen mice received intraperitoneal (IP) administration of anti-CCL-2 at a concentration
of 6.0 mg/kg/dose given on days 0 (tumor = 75 mm3), 3, 6, and 9 (average of 2 mg/kg/day), and
15 control mice received equivalent saline by a graduate student.

4.3 Preparation of the Tissue
4.3a Preservation
At each endpoint, each mouse was euthanized by a graduate student and the tumor was
subsequently surgically removed and flash frozen in liquid nitrogen. Anesthesia is typically used
in experiments involving animals because it reduces stress, and allows for easier manipulation of
the animals so injections of cancer cells and anti-cancer agents and any surgical procedures are
carried out unhindered. [17] Anesthetic agents used in mouse studies can be delivered via
inhalation or injection [17]. In this experiment, the mice were anesthetized via isoflurane
inhalation, which is a halogenated anesthetic gas. After being flash frozen, the bulk tumors were
embedded in OCT (Optimal Cutting Temperature compound) and frozen in a -80°C freezer for
long term preservation.
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4.3b Sectioning
The tumors were sectioned using cryosectioning techniques. A Leica CM3050 S Research
cryostat was used to section the tissue. A cryostat is a microtome inside a freezer that can be used
to create thin sections of tissue for microscopy. The cryostat was kept at -20°C and the tissue was
sliced in 6 µm sections. Once cut, the tissue sections were mounted on 22 x 40mm VWR
Microscope Cover Glasses that have a lysine coating to make them positively charged. This
positive charge allows for negatively charged tissue to adhere to the coverslip better. One slide
was prepared per mouse, and each slide contained 2 tumor sections for a total of 60 tumor sections
in this experiment.

4.3c Application of Antibody and Staining
Immunohistochemistry was performed at different time points (days 1, 4, 7, and 10). Alexa
Fluor 594 anti-mouse CD206 antibody (M2 macrophage count) was applied to the prepared tissue
sections, and the sections were washed with PBS-t (Phosphate Buffered Saline solution with
Tween). The tissue sections were then stained for DAPI (total cell content and macrophage
fraction). The primary antibody was already fluorescently tagged, and DAPI is a fluorescent stain
that binds strongly to DNA found in cell nuclei. The stains aided in understanding how anti-CCL2 immunotherapy affects total M2 count over time. An immediately adjacent tissue section of
control tumors on days 4,7, and 10 and an experimental tumor on day 10 were also stained with
Hematoxylin and Eosin to visualize the bulk tumors for size comparison and reference for imaging.
This stains proteins in the cytoplasm pink and the nucleus purple. The antibody staining protocol
used in this experiment can be found in Table 1. Figure 4 includes a flowchart of the experiment
from injecting the CT26 cells through the staining procedure.
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Figure 4. Flowchart of experimental methods from the injection of the immunotherapy to
the application of the antibody.

4.4 Imaging
A Nikon Eclipse Ni-U multi-color fluorescent
imaging microscope with a Lumencor SOLA SM6LCR-SB light engine lamp and a Nikon DS Qi1Mc
cooled, digital monochrome camera were used to image
the tumor sections and determine the M2 macrophage
density. The objective on the microscope was a 20X
magnification with a 0.50 numerical aperture. The two
filter cubes that were used on the microscope were
DAPI, and Texas-Red. Figure 5 is an image of the
microscope and camera setup, including the objective
used.

Figure 5. Nikon Eclipse Ni-U microscope
with a Lumencor SOLA Light engine lamp
and a Nikon DS Qi1camera.
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Once the microscope, camera, and lamp were turned on, the microscope was switched to
the 4X/.25NA objective, and the exposure was set to 100ms. The desired slide was then placed on
the microscope stage, and the filter wheel was turned to the DAPI filter. The course focus was
used to locate the top of the tissue, and the translation stage was moved so the first image taken
was halfway between the left and right edge of the tumor. The fine focus was then used to bring
the cells into focus. The image was then captured and saved as a “.tif” file. The filter was then
changed to the Texas Red filter and the fine focus was adjusted until the M2 macrophages were
clear. Another image was taken and saved as a “.tif” file. These steps were done for each field of
view and were repeated until 20 high-powered fields-of-view were acquired.
After the slides were imaged, the M2 macrophages were manually counted from the raw
images. Afterwards, ImageJ was used to process the images and obtain representative images.
Colors were assigned to the raw images, and the images were merged to create a composite image
overlaying the two-colored images. Red was chosen to represent M2 macrophages because the
antibody that was used to stain the M2 macrophages was fluorescently tagged with a fluorophore
that is excited from 590nm to 617 nm, which is in the red wavelength. Blue was chosen to represent
DAPI, because it emits a blue fluorophore.

5. Results
This experiment resulted in a visual decrease in the number of M2 macrophages between the
control mice and those treated with anti-CCL-2 immunotherapy. Figure 6 shows the various stages
of tumor growth on an untreated mouse, and Figure 7 is a graph of the bulk tumor growth from
day 0 to day 20. Day 0 was designated as when the tumor reached 75mm3.
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Figure 6. Control tumors sectioned and stained with Hematoxylin and Eosin, to show the growth of the
untreated tumors from days 4 to 10.

Figure 7. Graph of bulk tumor growth in an untreated, control mouse from
day 0 to day 20.
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Figure 8 includes a visual representation of the location of the field of views on a bulk tumor, and
highlights the location of an overlaid composite image after processing with ImageJ. These
findings can be seen in Figure 9.

Figure 8. (left) Control tumor
sectioned
and
stained
with
Hematoxylin and Eosin. (right)
Overlaid images from the DAPI and
Texas Red filters showing total cells
(blue) and M2 macrophages (red). The
field of view is .0152mm2.

Figure 9. Stained tumor sections on Day 10 of treatment. M2 macrophages are colored red and
total cells are colored blue. One can clearly see a decrease in the number of M2 macrophages
present in the tissue section treated with immunotherapy treatment.
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There was also a significant reduction in tumor growth rate and a decrease in M2
macrophage density in the mice administered anti-CCL-2 immunotherapy as compared to the
+
untreated control mice. On Day 10, the tumors were 13.02 +
−3.04 and 11.03 −3.99 times their
2
+
original sizes, and M2 macrophage densities were 593.3+
−9.0 and 559.2 −7.0 M2 macrophages/mm

for the control and treated mice respectively. Statistical analysis on the results was performed using
a two-tailed t-test with p-values less than 0.1. Graphical representations of the results can be seen
in Figure 10 and Figure 11.

Normalized Tumor Volume in Response to Tumor Therapy

Figure 10. Graph of tumor size in response to immunotherapy. The data was normalized to the
tumor on day zero (75mm3). **p< .01 via two-tailed t-test.
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Figure 11. Graph of M2 macrophage density after immunotherapy. The data was normalized
to the tumor on day zero (75mm3). **p< .01 via two-tailed t-test.

6. Discussion and Future Work
The results of this experiment will be used to guide immunotherapy in CRC by quantifying
the effects that blocking TAM recruitment via CCL-2 blockade has on the M2 macrophage density.
The second phase of this experiment is to determine the effects of traditional chemotherapy
treatment with 5-flurouracil vs. a combination of traditional chemotherapy treatment with
immunotherapy treatment on M2 macrophage density. Figure 12 is a diagram of the two phases
of this experiment. The intent behind this is to determine the best form of therapy by determining
which treatment method has the smallest density of M2 macrophages after treatment.
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Future work will investigate the effects of combining traditional 5-FU chemotherapy with
immunotherapy, and tumor therapeutic response by quantifying tumor hemoglobin and
oxygenation using Diffuse Reflectance Spectroscopy.

Figure 12. Diagram of the overall research project and future direction until completion.

18

7. Acknowledgements
This research would not have been possible without the guidance and support of my faculty
mentor, Dr. Muldoon, and the graduate student I researched under, Gage Greening. I also want to
thank Sandra Prieto, Haley James, and Shelby Bess for their contributions to my research project.
Funding of this project was provided by the National Institutes of Health, National Science
Foundation, and the Arkansas Department of Higher Education State Undergraduate Research
Fellowship (SURF). I would also like to thank the Honors College at the University of Arkansas
for allowing me to write and present my research in the form of an Honors Thesis. I began college
in an honors undergraduate research course, and I would not have made the connections with Dr.
Muldoon and had the experiences that I have had without being in that course my freshman year.
Finally, I would like to acknowledge the University of Arkansas Biomedical Engineering
Department for providing the equipment and lab facilities to conduct this research.

19

8. References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. A Cancer Journal for Clinicians.
2017;67(1):7-30. doi: 10.3322/caac.21387.
2. Lacunza, Ezequiel, R. Canzoneri, M. E. Rabassa, A. Zwenger, A. Segal-eiras, M. V. Croce,
and M. C. Abba. "RHBDD2: A 5-Fluorouracil Responsive Gene Overexpressed in the
Advanced Stages of Colorectal Cancer." Tumor Biology 33, no. 6 (12, 2012): 2393-9.
3. Ferrari L, Fichera A. Neoadjuvant chemoradiation therapy and pathological complete response
in rectal cancer. Gastroenterology Report. 2015;3(4):277-88. doi: 10.1093/gastro/gov039
4. Zhang, Tianqian, and Dorothee Herlyn. 2009. Combination of active specific immunotherapy
or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of
cancer. Cancer
Immunology,
Immunotherapy58,
(4)
(04):
475-92,
http://0search.proquest.com.library.uark.edu/docview/213519386?accountid=8361 (accessed March
29, 2018).
5. Kaler, Pawan, Vincent Galea, Leonard Augenlicht, and Lidija Klampfer. 2010. "Tumor
Associated Macrophages Protect Colon Cancer Cells from TRAIL-Induced Apoptosis through
IL-1beta]- Dependent Stabilization of Snail in Tumor Cells." PLoS One 5 (7).
6. Isidro, R. A., & Appleyard, C. B. (2016). Colonic macrophage polarization in homeostasis,
inflammation, and cancer. American Journal of Physiology - Gastrointestinal and Liver
Physiology, 311(1), G59–G73. http://0-doi.org.library.uark.edu/10.1152/ajpgi.00123.2016.
7. Fridlender, Z. G., A. Jassar, I. Mishalian, L. -cs Wang, V. Kapoor, G. Cheng, J. Sun, S. Singhal,
L. Levy, and S. M. Albelda. 2013. "Using Macrophage Activation to Augment Immunotherapy
of Established Tumours." The British Journal of Cancer 108 (6): 1288-97.
8. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation
in colorectal cancer. Cancer Microenviornment. 2011;4:141-54. doi: 10.1007/s12307-0100052-5.
9. Petrillo, Marco, Gian Franco Zannoni, Enrica Martinelli, Luigi Pedone Anchora, Gabriella
Ferrandina, Giovanna Tropeano, Anna Fagotti, and Giovanni Scambia. 2015. "Polarisation of
Tumor-Associated Macrophages Toward M2 Phenotype Correlates with Poor Response to
Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer."
PLoS One 10 (9).
10. Song, Zhenguo, He Ren, Song Gao, Tiansuo Zhao, Xiuchao Wang, Shengjie Zhang, Xiao
Zhao, Lingling Jia, Junwei Sun, and Jihui Hao. 2013. The hypoxia-inducible factor-1 regulates
the microRNA185 expression through binding to hypoxia response elements sequence
2. Medical
Oncology 30,
(4)
(12):
1-10,
http://0search.proquest.com.library.uark.edu/docview/1461633418?accountid=8361
(accessed
March 29, 2018).

20

11. De ́ry MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and
non-hypoxic activators. Int J Bio- chem Cell Biol. 2005;37:535–40.

12. Kejian, Z., Yaodong, W., Yan, H., Liansheng, Z., Wanfu, X., Guoxin, L. (2017). Specific
tumor-derived CCL2 mediated by pyruvate kinase M2 in colorectal cancer cells contributes to
macrophage recruitment in tumor microenvironment. Tumor Biology, 39(3),
https://doi.org/10.1177/1010428317695962.
13. Marech I, Ammendola M, Sacco R, Sammarco G, Zuccalà V, Zizzo, Leporini C, Luposella M,
Patruno R, Filippelli G, Russo E, Porcelli M, Gadaleta CD, De Sarro G, Ranieri G. Tumour‐
associated macrophages correlate with microvascular bed extension in colorectal cancer
patients. Journal of Cellular and Molecular Medicine. 2016;20(7):1373-80. doi:
10.1111/jcmm.12826.
14. Williams, Kaye J., Brian A. Telfer, Rachel E. Airley, Hans PW Peters, Mary R. Sheridan, der
Kogel Albert J van, Adrian L. Harris, and Ian J. Stratford. 2002. A protective role for HIF-1 in
response to redox manipulation and glucose deprivation: Implications for
tumorigenesis. Oncogene 21,
(2)
(Jan
10):
282-90,
http://0search.proquest.com.library.uark.edu/docview/227312386?accountid=8361 (accessed March
29, 2018).
15. Kizaka-Kondoh S, Tanaka S, Harada H, et al. The HIF-1-active microenvironment: an
environmental target for cancer therapy. Adv Drug Deliv Rev. 2009;61(7–8):623–32.

16. Peddareddigari, V. G., Wang, D., & DuBois, R. N. (2010). The Tumor Microenvironment in
Colorectal
Carcinogenesis. Cancer
Microenvironment, 3(1),
149–166.
http://doi.org/10.1007/s12307-010-0038-3.
17. S. Gargiulo, A. Greco, M. Gramanzini, S. Esposito, A. Affuso, A. Brunetti, and G. Vesce,
"Mice anesthesia, analgesia, and care, Part I: anesthetic considerations in preclinical research,"
Institute for Laboratory Animal Research Journal 53(2012).
18. “10 Warning Signs of Colon Cancer You Shouldn’t Ignore.” Top 10 Home Remedies. August
19, 2017. Accessed March 15, 2018. https://www.top10homeremedies.com/news-facts/10warning-signs-of-colon-cancer.html.
19. "Cancer
Immunotherapy."
Sanford
Health.
Accessed
March
15,
http://www.sanfordhealth.org/sioux-falls/services/head-neck-cancer/research/cancerimmunotherapy.

2018.

21

9. Appendix
Table 1. A step-by-step breakdown of the staining protocol used in this experiment.
Step

Activity

Quantity

Contents

Light

Temp.

Time (min)

1

Prepare Blocking
Solution

800µL

Yes

Room

5

2

Prepare slides
for staining

10

Goat-based
blocking
solution
Slides
containing
tissue sections

Yes

-20˚C

20

3

Dispense Buffer
and Antibody

1:125

No

Room

5

4

Prepare Series of 4 jars
Solution Boxes each with
90mL of
solution

Universal
Antibody
dilution buffer
and AntiCD206 mix
-Acetone
-PBS-t
(acetone)
-PBS-t (M2)
-PBS-t
(M2/DAPI)

Yes

-20 ˚C
Room
Room
Room

20

5

Fixation of
Slides With
Acetone

10

Slides in
Acetone

Yes

0 ˚C

10

6

Washing Slides
with PBS-t

10

Slides in PBS-t
(acetone)

Yes

Room

3

7

Addition of
Blocking
Solution

80µL

Goat-based
blocking
solution

Yes

Room

3

8

Place Slides in
Dark Humidified
Chamber

10

Slides with
goat-based
blocking
solution

No

Room

60

22

9

Addition of
Buffer and
Antibody Mix

100 µL

10

Place Slides in
Dark Humidified
Chamber
Washing Slides
with PBS-t
Adding DAPI

10

11
12
13
14

15

Washing Slides
with PBS-t
Mounting the
Coverslips

Sealing Slides

10
1 drop
per slide
10
10

10

1:125
Universal
Antibody
dilution buffer
and AntiCD206 mix
Slides with
buffer and
antibody mix
Slides in PBS-t
(M2)
DAPI

No

Room

3

No

Room

90

No

Room

No

Room

Stable: 6
Moving: 1
1

Slides in PBS-t
(M2/DAPI)
-Stained slides
-22x40
coverslip
-Fluoromount
G
-Coverslipped
slides
-Nail Polish

No

Room

No

Room

Stable: 6
Moving: 1
8

No

Room

60
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